[Cortexin in the comprehensive therapy of alcoholic encephalopathy]

To evaluate the efficacy, safety, and dose-dependent effects of Cortexin in the comprehensive therapy of alcoholic encephalopathy (EA).

This study was conducted from April 2025 to November 2025 and included 40 patients (20 females and 20 males), aged 34-72 years (mean age: 52.7±14.2 years). Participants received intramuscular injections of Cortexin at 10 mg (n=20) or 20 mg (n=20) for 10 days. The comprehensive treatment regimen included hepatoprotective, metabolic, and detoxification therapies. Each patient was evaluated over a span of 10 days, which included two clinical visits: a neuropsychological assessment on day 1 (the day of hospital admission) and a follow-up on day 10, using standardized neuropsychological methods, specifically the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Schulte tables.

The incorporation of Cortexin, both at 10 mg and 20 mg, into the comprehensive therapy resulted in notable improvements, characterized by a reduction in symptoms and a statistically significant enhancement in neuropsychological test scores: MMSE scores improved from 27.3 to 28.9 points (p<0.01), FAB scores increased from 15.5 to 17.1 points (p<0.01), and performance with the Schulte tables improved from an average of 97.5 seconds to 84.5 seconds (p<0.05) in both patient groups. These findings demonstrate the efficacy of Cortexin in addressing cognitive deficits.

The implementation of comprehensive therapy with Cortexin at dosages of 10 mg and 20 mg resulted in significant improvements in cognitive function among patients with alcoholic encephalopathy. The pharmacological properties of this medication render it an essential component of comprehensive treatment strategies aimed at the restoration of memory and cognitive capabilities, thereby enhancing the quality of life for patients with alcoholic encephalopathy.